OMCL · Omnicell, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on OMCL. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About OMCL · Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Live Quote
SELL (score -3) · 12-1 mom 50.4% · RSI 40 · below_both · -25.3% from high
Targets blend Wall Street consensus (7 analysts: low $55.00 / mean $61.29 / high $70.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.
The dossier shows no insider conviction, an already-priced-in catalyst, and weak quality metrics (ROIC 1.3%). Anti-signal gates for dilution and low liquidity further invalidate the setup, making it a mediocre, over-extended trade with no clear structural edge.
The investigation found no open-market insider purchases (P-codes) — all four Form 4s filed May 19 report F-codes (RSU tax withholding by the CEO, CFO, CAO, and CLO) or S-codes (Rule 10b5-1 scheduled sales). Nnamdi Njoku's April RSU grant (A-code, $0 exercise) is compensation equity, not a discretionary buy. The filing cluster triggering this investigation was routine vesting-related activity misidentified as insider conviction. Q1 2026 earnings beat expectations with 15% revenue growth and margin expansion, prompting analyst target raises to $55-$70, but the stock has already rallied ~20% from its October low and sits near the upper portion of its 52-week range with limited apparent upside vs. consensus targets.